Your browser doesn't support javascript.
loading
Prognostic and immunological significance of metastasis-associated protein 3 in patients with thymic epithelial tumors.
Li, Jinping; Deng, Zhenyan; Liu, Yu; Jin, Jiamin; Xie, Chichu; Gan, Jinfeng.
Afiliação
  • Li J; Department of Histology and Embryology, School of Preclinical Medicine, Guilin Medical University, Guilin, China.
  • Deng Z; Department of Clinical Laboratory, Guilin Hospital of the Second Xiangya Hospital CSU, Guilin, China.
  • Liu Y; Guangxi Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin, China.
  • Jin J; Guangxi Health Commission Key Laboratory of Tumor Immunology and Receptor-Targeted Drug Basic Research, Guilin Medical University, Guilin, China.
  • Xie C; Clinical Research Center, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, China.
  • Gan J; Guangxi Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin, China.
Discov Oncol ; 15(1): 216, 2024 Jun 09.
Article em En | MEDLINE | ID: mdl-38852126
ABSTRACT

BACKGROUND:

Immune checkpoint inhibitors have shown promising anticancer activity and have recently been proposed as a therapy for thymic epithelial tumors (TETs); however, this treatment is only effective for a subgroup of TET patients. Thus, this study aims to identify the potential genes implicated in the regulation of cancer immunity in TETs.

METHODS:

The TETs RNA-seq and clinical data were obtained from The Cancer Genome Atlas (TCGA) database. The clinical significance of the tumor microenvironment (TME) in TETs was evaluated. Weighted gene coexpression network analysis (WGCNA) was used to identify the immune response-related hub genes. The expression of metastasis-associated protein 3 (MTA3) in TETs was investigated in public datasets and a patient cohort. Kaplan‒Meier curves were generated to analyze the prognostic value of various factors. The Tumor Immune Estimation Resource (TIMER2.0) was used to estimate the relevance of MTA3 to immune cell infiltration. Gene set enrichment analysis (GSEA) and pathway enrichment analysis were applied to explore the MTA3-related pathways.

RESULTS:

The TME was found to be clinically significant in TETs. Moreover, MTA3 was identified as a key gene associated with the immune score, and lower MTA3 expression was linked to poor TME and reduced cytotoxic activity in TETs. Furthermore, MTA3 was found to be deregulated in TETs, predictive of poor prognosis. MTA3 was also significantly associated with the infiltration levels of various immune cell types and highly correlated with their corresponding markers. Notably, MTA3 was positively associated with various immune response pathways.

CONCLUSION:

MTA3 is clinically significant in TETs and correlated with immune cell infiltration. Thus, MTA3 might be a biomarker for predicting the prognosis and immune status of TET patients.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Discov Oncol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Discov Oncol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China